Karuna Therapeutics Submits New Drug Application To FDA For KarXT For The Treatment Of Schizophrenia
Portfolio Pulse from Benzinga Newsdesk
Karuna Therapeutics has submitted a new drug application to the FDA for KarXT, a treatment for schizophrenia. Schizophrenia affects nearly 24 million people worldwide, including 2.8 million people in the U.S.
September 28, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karuna Therapeutics' submission of a new drug application for KarXT could potentially boost its stock as it represents a significant step in the drug's development process.
The submission of a new drug application is a significant step in the drug development process. If approved, KarXT could potentially generate significant revenue for Karuna Therapeutics, which would likely have a positive impact on its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100